EPISURF MEDICAL AB Financials Episurf Medical AB
Equities
EPIS B
SE0003491562
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.359 SEK | -2.45% |
|
-49.44% | -63.74% |
| Apr. 24 | Episurf Medical Announces Distributor Agreement with Depuy-Synthes | CI |
| Apr. 24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 106.4 | 672.8 | 1,213 | 627.2 | 264.4 | 96.05 | - | - |
| Enterprise Value (EV) 1 | 86.99 | 517.8 | 974.9 | 471.9 | 206.5 | -11.95 | 149 | 120 |
| P/E ratio | -1.13 x | -7.77 x | -14.7 x | -8.1 x | -2.75 x | -2.39 x | -3.71 x | -5.98 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 21.7 x | 96.1 x | 176 x | 90.9 x | 24.9 x | 5.61 x | 2.62 x | 1.49 x |
| EV / Revenue | 17.8 x | 74 x | 141 x | 68.4 x | 19.5 x | -0.7 x | 4.06 x | 1.86 x |
| EV / EBITDA | -1.41 x | -9.04 x | -15.7 x | -6.74 x | -2.35 x | 0.19 x | -2.91 x | -2.82 x |
| EV / FCF | -1.34 x | -8.82 x | -16.3 x | -5.85 x | -2.19 x | 0.16 x | -2.46 x | -2.33 x |
| FCF Yield | -74.4% | -11.3% | -6.13% | -17.1% | -45.7% | 619% | -40.6% | -42.9% |
| Price to Book | 2.57 x | 3.99 x | 4.79 x | 3.53 x | 3.14 x | 1.35 x | 2.12 x | - |
| Nbr of stocks (in thousands) | 90,931 | 222,041 | 266,540 | 266,912 | 267,065 | 267,539 | - | - |
| Reference price 2 | 1.170 | 3.030 | 4.550 | 2.350 | 0.9900 | 0.3590 | 0.3590 | 0.3590 |
| Announcement Date | 2/7/20 | 2/19/21 | 2/11/22 | 2/17/23 | 2/9/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.9 | 7 | 6.9 | 6.9 | 10.6 | 17.12 | 36.71 | 64.5 |
| EBITDA 1 | -61.5 | -57.3 | -62 | -70 | -88 | -64.38 | -51.29 | -42.5 |
| EBIT 1 | -68.9 | -64.9 | -69.4 | -77 | -96.7 | -71.43 | -58.64 | -49.5 |
| Operating Margin | -1,406.12% | -927.14% | -1,005.8% | -1,115.94% | -912.26% | -417.16% | -159.71% | -76.74% |
| Earnings before Tax (EBT) 1 | -69.8 | -63.9 | -69.2 | -77.2 | -94.6 | -69.58 | -57.09 | -48 |
| Net income 1 | -69.8 | -63.9 | -69.3 | -77.3 | -94.8 | -69.58 | -57.09 | -48 |
| Net margin | -1,424.49% | -912.86% | -1,004.35% | -1,120.29% | -894.34% | -406.36% | -155.49% | -74.42% |
| EPS 2 | -1.040 | -0.3900 | -0.3100 | -0.2900 | -0.3600 | -0.1502 | -0.0967 | -0.0600 |
| Free Cash Flow 1 | -64.7 | -58.7 | -59.8 | -80.7 | -94.3 | -74 | -60.5 | -51.5 |
| FCF margin | -1,320.41% | -838.57% | -866.67% | -1,169.57% | -889.62% | -432.18% | -164.79% | -79.84% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/7/20 | 2/19/21 | 2/11/22 | 2/17/23 | 2/9/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.6 | 1.9 | - | 2 | 2.5 | 4.7 | - | 3.2 | 4 | 3.8 | 4.7 | 6.2 |
| EBITDA 1 | -14.5 | -17.6 | - | -22.3 | -21.2 | -27.7 | -17.3 | -21.7 | -18.5 | -15.3 | -14.9 | -15.5 |
| EBIT 1 | -16.3 | -19.4 | - | - | -23.1 | - | - | -24 | -20.6 | -16.7 | -16.2 | -16.9 |
| Operating Margin | -1,018.75% | -1,021.05% | - | - | -924% | - | - | -750% | -515% | -439.47% | -344.68% | -272.58% |
| Earnings before Tax (EBT) | -16.4 | -19.3 | - | - | - | - | - | - | - | - | - | - |
| Net income | -16.4 | -19.4 | -17.8 | - | - | - | - | - | - | - | - | - |
| Net margin | -1,025% | -1,021.05% | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | -0.0700 | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 4/29/22 | 7/15/22 | 11/16/22 | 2/17/23 | 4/28/23 | 7/14/23 | 10/27/23 | 2/9/24 | 4/24/24 | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 53 | 24 |
| Net Cash position 1 | 19.4 | 155 | 238 | 155 | 57.9 | 108 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -1.033 x | -0.5647 x |
| Free Cash Flow 1 | -64.7 | -58.7 | -59.8 | -80.7 | -94.3 | -74 | -60.5 | -51.5 |
| ROE (net income / shareholders' equity) | -162% | -60.6% | -32.8% | -35.9% | -72.3% | -64.6% | -54.7% | -99.6% |
| ROA (Net income/ Total Assets) | -124% | -52.6% | -30.4% | -33% | -83.9% | -56.1% | -36.5% | -32.3% |
| Assets 1 | 56.2 | 121.5 | 228 | 233.9 | 113 | 124 | 156.4 | 148.6 |
| Book Value Per Share 2 | 0.4600 | 0.7600 | 0.9500 | 0.6700 | 0.3200 | 0.2700 | 0.1700 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 5.5 | 4.6 | 0.1 | - | - | - | 1 | 1 |
| Capex / Sales | 112.24% | 65.71% | 1.45% | - | - | - | 2.72% | 1.55% |
| Announcement Date | 2/7/20 | 2/19/21 | 2/11/22 | 2/17/23 | 2/9/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -63.74% | 8.76M | |
| +12.07% | 128B | |
| -9.04% | 10.65B | |
| +0.91% | 8.82B | |
| +16.72% | 7.19B | |
| +25.15% | 4.99B | |
| +7.17% | 3.4B | |
| -1.36% | 3.03B | |
| -8.73% | 2.14B | |
| -10.15% | 2B |
- Stock Market
- Equities
- EPIS B Stock
- Financials Episurf Medical AB
